GlassScriptPhysician profile
Paul P Maraj
NPI 1114214301
$2,782.40
in general payments reported to CMS, 2019-2025
28 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $138 · 2021: $130 · 2022: $139 · 2023: $585 · 2024: $413 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869 · Education: $80.29 · Consulting Fee: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.80 |
| Education | $80.29 |
| Consulting Fee | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $411.24 | 2020-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $365.74 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $315.14 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $269.56 | 2020-2025 | Veltassa |
| Travere Therapeutics, INC. | $167.55 | 2019-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $166.91 | 2025 | |
| Akebia Therapeutics INC | $165.31 | 2019-2025 | Vafseo |
| Amgen INC. | $125.50 | 2021-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $110.30 | 2019-2024 | Rayaldee |
| Scpharmaceuticals INC. | $102.95 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $81.34 | 2019 | |
| Glaxosmithkline, LLC. | $80.00 | 2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $68.20 | 2023-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.07 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $31.05 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $30.62 | 2022 | |
| Boston Scientific Corporation | $29.70 | 2022 | |
| Ardelyx, INC. | $28.23 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $24.12 | 2021 | |
| Lilly USA, LLC | $23.45 | 2025 | Jardiance |
| Novo Nordisk INC | $21.33 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $21.09 | 2023 | |
| Shire North American Group INC | $19.37 | 2019 | |
| Cormedix INC. | $18.31 | 2025 | Defencath |
| Nxstage Medical, INC. | $16.81 | 2019 | |
| Philips North America LLC | $16.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.35 | 2019 | |
| Genentech USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Maraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.